Characteristics of Patients Before Infusion of Donor Leukocytes and Number of CD3+ Cells Infused
| Pt . | Age (yr)/Sex . | Disease Status at BMT . | Donor Sex . | BMT: Conditioning Therapy . | GVHD Prophylaxis . | BMT to Molec. Rel. in mo . | BMT to Hemat. Rel. in mo . | Hemat. Relapse to First DLI . | Treatment of Relapse Before DLI . | Disease Status Before DLI . | CD3+ Cells × 109/kg b/w Infused . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1a | 37/M | Ph+ ALL, primary refractory | M | AraC/VP16/TBI | CSA | NA | NA | NA | No | Mol rel | 4.05 |
| 1b | NA | 9 | No | Hemat rel | 4.48 | ||||||
| 2 | 52/M | CML, CP1 | M | CY/TBI | CSA/MTX | 3 | 9 | 17 | INF-α | Hemat rel | 4.48 |
| 3 | 28/F | CML, CP1 | M | CY/TBI | CSA/MTX | 36 | 54 | 6 | INF-α | Hemat rel | 4.36 |
| 4 | 36/F | CML, CP1 | M | CY/TBI | CSA | 82 | NA | NA | INF-α | Cytog rel | 0.5 |
| 5a | 28/F | MDS with sec. AML | M | CY/TBI | CSA/MTX | NA | 43 | 0.5 | No | Hemat Rel | 1.2 |
| 5b | NA | NA | Chemotherapy | CR2 | 1.04 | ||||||
| 6 | 28/M | AML, CR1 | F | CY/TBI | CSA/MTX | NA | 26 | 3 | Chemotherapy | CR2 | 1 |
| 7 | 31/M | AML, CR2 | F | CY/TBI | CSA/MTX | NA | 16 | 3 | Chemotherapy | CR3 | 0.5 |
| Pt . | Age (yr)/Sex . | Disease Status at BMT . | Donor Sex . | BMT: Conditioning Therapy . | GVHD Prophylaxis . | BMT to Molec. Rel. in mo . | BMT to Hemat. Rel. in mo . | Hemat. Relapse to First DLI . | Treatment of Relapse Before DLI . | Disease Status Before DLI . | CD3+ Cells × 109/kg b/w Infused . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1a | 37/M | Ph+ ALL, primary refractory | M | AraC/VP16/TBI | CSA | NA | NA | NA | No | Mol rel | 4.05 |
| 1b | NA | 9 | No | Hemat rel | 4.48 | ||||||
| 2 | 52/M | CML, CP1 | M | CY/TBI | CSA/MTX | 3 | 9 | 17 | INF-α | Hemat rel | 4.48 |
| 3 | 28/F | CML, CP1 | M | CY/TBI | CSA/MTX | 36 | 54 | 6 | INF-α | Hemat rel | 4.36 |
| 4 | 36/F | CML, CP1 | M | CY/TBI | CSA | 82 | NA | NA | INF-α | Cytog rel | 0.5 |
| 5a | 28/F | MDS with sec. AML | M | CY/TBI | CSA/MTX | NA | 43 | 0.5 | No | Hemat Rel | 1.2 |
| 5b | NA | NA | Chemotherapy | CR2 | 1.04 | ||||||
| 6 | 28/M | AML, CR1 | F | CY/TBI | CSA/MTX | NA | 26 | 3 | Chemotherapy | CR2 | 1 |
| 7 | 31/M | AML, CR2 | F | CY/TBI | CSA/MTX | NA | 16 | 3 | Chemotherapy | CR3 | 0.5 |
Abbreviations: Pt, patient, AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CP, chronic phase; CR, complete remission; INF-α, interferon-α; rel, relapse; cytog, cytogenetic, molec, molecular; hemat, hematological; NA, not applicable; M, male, F, female; CY, cyclophosphamide; CSA, cyclosporine; MTX, methotrexate; AraC, cytosine arabinoside; VP16, etoposide; sec., secondary.